FibroBiologics Achieves Milestone with HREC Approval
FibroBiologics, Inc. (NASDAQ: FBLG), a pioneering clinical-stage biotechnology company known for its extensive portfolio of over 270 patents, has gained significant recognition after receiving crucial approvals from the Human Research Ethics Committee (HREC) in Australia. This green light allows the commencement of a Phase 1/2 clinical trial designed to investigate CYWC628, an innovative therapy aimed at treating refractory diabetic foot ulcers (DFU).
Overview of the Clinical Trial
This trial has been meticulously planned to include 120 patients across ten different sites in Australia. The recent approval signifies that FibroBiologics has completed all necessary regulatory filings to embark on this venture. Given the seriousness of diabetic foot ulcers, this trial holds great promise not just for patients but also for advancing medical science.
Collaboration with Southern Star Research
In this ambitious project, FibroBiologics has chosen Southern Star Research, a respected full-service Contract Research Organization (CRO), for managing all aspects of the clinical trial. Lloyd Prescott, the CEO of Southern Star, expressed his enthusiasm for the collaboration, praising FibroBiologics' dedication to breakthroughs in cell therapy and regenerative medicine.
The Clinical Trial Protocol
The structure of the trial is a prospective, multicenter, randomized study which will explore the safety, tolerability, and efficacy of CYWC628. Participants will receive treatment for a maximum of 12 weeks, receiving either standard care along with varying doses of CYWC628 or standard care alone. The goal is to identify how effectively this new therapy can improve wound healing outcomes.
Critical Assessment and Outcomes
Throughout the trial, extensive monitoring will occur to evaluate both clinical and imaging outcomes, focusing on the response efficacy and safety of the therapy. An interim analysis is planned after a specific number of participants have completed the initial six-week treatment period, providing an early indication of the trial's success.
Vision for FibroBiologics
CEO Pete O’Heeron shared his enthusiasm about the HREC approvals, describing them as pivotal in the journey of bringing innovative fibroblast-based therapies to patients. He emphasized that this clinical trial represents a transition from laboratory research to real-world application, potentially paving the way to new treatment avenues for chronic wounds that have historically been challenging to manage.
Advancing Wound Healing Solutions
This study promises not only to affirm the safety and potential benefits of CYWC628 but also aims to generate vital clinical data. This information could establish CYWC628 as an essential option in the field of chronic wound management. The need for effective treatments has never been more critical, and FibroBiologics is committed to meeting this challenge with cutting-edge therapies.
About CYWC628
CYWC628 features a promising formulation as a topically administered allogeneic fibroblast cell-based treatment designed for wound healing. Preliminary findings highlight its potential to significantly enhance healing rates compared to existing treatment methods. FibroBiologics is eager to test this in their upcoming clinical trial.
About FibroBiologics
Operating from Houston, FibroBiologics is honing in on developing advanced treatments for chronic diseases through specialized fibroblast technology. With its vast portfolio, the company isn't merely aiming for improved healthcare outcomes but is focused on redefining the standards in cell therapy and tissue regeneration.
Contact Information
For media inquiries, reach out to FibroBiologics via email at info@fibrobiologics.com. For investor relations, Nic Johnson of Russo Partners can be contacted at (212) 845-4242, or through email at fibrobiologicsIR@russopr.com. For media-related concerns, Liz Phillips can be contacted at (347) 956-7697 or via email at Elizabeth.phillips@russopartnersllc.com.
Frequently Asked Questions
What is the focus of the clinical trial by FibroBiologics?
The clinical trial aims to evaluate the safety, tolerability, and efficacy of CYWC628 in treating refractory diabetic foot ulcers.
How many patients will participate in the trial?
120 patients will be enrolled in the study across ten different sites in Australia.
What collaboration does FibroBiologics have for this trial?
FibroBiologics is collaborating with Southern Star Research, a reputable Contract Research Organization managing the trial.
What is CYWC628?
CYWC628 is a novel allogeneic fibroblast cell-based therapy targeted at enhancing wound healing.
What are the expected outcomes of the clinical trial?
The trial aims to assess improvements in wound healing, overall safety, and effectiveness of the new treatment compared to standard care.
